This study leveraged real‐world data from the EnRICH database to investigate real‐world first‐ and second‐line treatment strategies in EGFR oncogene‐driven NSCLC, patterns of disease progression, and compared survival outcomes to guide treatment strategies moving forward. This evidence concerns the gene EGFR and non-small cell lung carcinoma.